During the past decade, Fukui-Ken Saiseikai Hospital conducted 14 clinical trials. In the 10-year time frame, 14 clinical trials started and 6 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 6 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Fukui-Ken Saiseikai Hospital" #1 sponsor was "Boehringer Ingelheim" with 4 trials, followed by "Gilead Sciences" with 3 trials sponsored, "Bayer" with 2 trials sponsored, "Japan Clinical Cancer Research Organization" with 2 trials sponsored and "Pfizer" with 2 trials sponsored. Other sponsors include 1 different institutions and companies that sponsored additional 10 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fukui-Ken Saiseikai Hospital" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Tokyo Medical and Dental University" with 2 trials as a collaborator, "Korean Cancer Study Group" with 1 trials as a collaborator, "Novo Nordisk A/S" with 1 trials as a collaborator and "Taiho Pharmaceutical Co., Ltd." with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Fukui-Ken Saiseikai Hospital" are "Colorectal Cancer" (2 trials), "Gastric Cancer" (2 trials), "Heart Failure" (2 trials), "Nonalcoholic Steatohepatitis" (2 trials) and "Anemia" (1 trials). Many other conditions were trialed in "Fukui-Ken Saiseikai Hospital" in a lesser frequency.

Most popular intervention types in "Fukui-Ken Saiseikai Hospital" are "Drug" (17 trials), "Biological" (1 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (9 trials), "Empagliflozin" (3 trials), "UFT adjuvant chemotherapy" (2 trials), "BI 456906" (1 trials) and "Cilofexor (CILO)/Firsocostat (FIR)" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fukui-Ken Saiseikai Hospital" are 19 trials for "All" genders.

Currently, there are NaN active trials in "Fukui-Ken Saiseikai Hospital". undefined are not yet recruiting, 2 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 12 completed trials in Fukui-Ken Saiseikai Hospital, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Fukui-Ken Saiseikai Hospital, 0 "Phase 1" clinical trials were conducted, 7 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".